# Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

> **NCT05852717** · PHASE2 · RECRUITING · sponsor: **Dipenkumar Modi** · enrollment: 32 (estimated)

## Conditions studied

- Large Cell Lymphoma, Diffuse
- Relapsed Cancer
- Refractory Cancer

## Interventions

- **PROCEDURE:** AutoSCT OR CAR T-cell Therapy
- **DRUG:** GDP
- **DRUG:** Epcoritamab

## Key facts

- **NCT ID:** NCT05852717
- **Lead sponsor:** Dipenkumar Modi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2027-11-24
- **Final completion:** 2028-11-24
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05852717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05852717, "Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT05852717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*